European experience of timentin in combination with aminoglycosides as empirical treatment in febrile neutropenic patients.
Croydon
E
E
Beecham Pharmaceuticals, European Division, Bruxelles, Belgium.
Weerts
D
D
D000328:Adult; D000380:Agranulocytosis / Q000150:complications*; D000583:Amikacin / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002648:Child; D002969:Clavulanic Acids / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D005335:Fever of Unknown Origin / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D009428:Netilmicin / Q000627:therapeutic use*; D009503:Neutropenia / Q000150:complications*; D010406:Penicillins / Q000627:therapeutic use*; D012189:Retrospective Studies; D018805:Sepsis / Q000150:complications / Q000188:drug therapy*; D013982:Ticarcillin / Q000627:therapeutic use*; D014031:Tobramycin / Q000627:therapeutic use*; D065093:beta-Lactamase Inhibitors
D002969:Clavulanic Acids; D010406:Penicillins; D065093:beta-Lactamase Inhibitors; D009428:Netilmicin; D000583:Amikacin; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin; D014031:Tobramycin